Abstract
Over the last two decades, four major therapeutic approaches have dramatically changed the prognosis in chronic myelogenous leukemia(CML). Those include allogeneic stem cell transplantation, interferon-alpha based regimen, donor-leukocyte infusions, and the revolutionary BCR/ABL tyrosine kinase inhibitor such as STI571. Each modality has exploited and targeted different aspects of CML biology, and is associated with different risk-benefit ratios. In this section, we update the results of both related and unrelated donor transplantation, donor lymphocyte infusions, and non-myeloablative stem cell transplantation in CML in comparison with the other treatment modalities.
| Original language | English |
|---|---|
| Pages (from-to) | 2375-2382 |
| Number of pages | 8 |
| Journal | Nippon rinsho. Japanese journal of clinical medicine |
| Volume | 59 |
| Issue number | 12 |
| Publication status | Published - 2001 Dec |
ASJC Scopus subject areas
- Medicine(all)